April 10, 2013
/PRNewswire-USNewswire/ -- The Rogosin Institute ("Rogosin" or "The Institute") announces with great pleasure the appointment of Richard Hall, Executive Vice President, Supply Chain, Engineering and Sustainability, Bob Evans Farms, Inc., as Chairman of the Board of Directors effective
March 13, 2013
Hall, closely affiliated with Rogosin since 1994 and a Board member since 2008, brings both a commitment to its vision for healthcare and a breadth of business expertise and experience to The Institute as it continues its path of growth and ever-improving quality of care and research to develop new approaches to treatment. He succeeds Rogosin's outgoing Board Chair,
, Chairman of First Reserve Capital of
Hall joined the Bob Evans Farms team in 1987 as plant manager at the
, facility. Over the past 26 years, he has held ever-increasing levels of responsibility at Bob Evans Farms including Sr. VP of Corporate Procurement and Vice President of Production. In his current role, he is responsible for all procurement for the company's Food Products and Restaurant divisions, restaurant distribution, transportation, strategic sourcing, facilities purchasing and distribution, livestock procurement and the organization's restaurant engineering and sustainability initiatives.
Rogosin and Bob Evans Farms began a unique relationship in 1994 to advance medical research. Bob Evans Farms donated laboratory space and an office at their
to Rogosin in an effort to make hog pancreas glands readily available for the advancement of Rogosin's diabetes research program in islet cell macroencapsulation and transplantation for the treatment of Type 1 diabetes. Richard took a personal interest in the project, assisted with all areas of operations, and further encouraged Bob Evans to donate land and help fund the construction of a separate laboratory, opened in 1997. The research at Rogosin's Xenia Division at Bob Evans Farms has expanded to include research involving a novel approach to the treatment of cancer.
Richard's involvement in assisting the advancement of both the diabetes and cancer research programs continues with tremendous passion and commitment. "Rogosin is both honored and fortunate to have
as its next Board Chair. His extraordinary leadership and dedication to Rogosin's mission will help guide our growth and success in the years ahead," commented
Barry H. Smith
, MD, PhD, President and CEO, Rogosin.
"As a long time member of The Rogosin Institute's Board, I've seen the impressive work that's been done by the organization and its members," Hall says. "I look forward to building upon their successes as we continue to expand our operations for kidney dialysis and the treatment of kidney disease as well as bring our research for two of the most devastating diseases - cancer and diabetes – to the patient's bedside. I can't imagine being engaged in a more rewarding initiative."